Designed to be worn on your wrist, MyAIWatch sTM life-saving
technology helps avoid overdoses and potentially life-
threatening drug interactions.
AGOURA HILLS CA [July 25, 2023] – MultiCorp International Inc (OTC Pink: MCIC –
News] today introduced a new Artificial Intelligence-based device that promises to
revolutionize medication management for the more than 131 million Americans
who rely on prescription drugs.
MyAIWatchTM, a patent-pending technology, is the brainchild of MCIC’s Acting CEO
Ben Friedman, whose 40+ years as a licensed pharmacist brought unique insights
into the technology and programming behind the new smart device. “MyAIWatch
addresses what I’ve found is the Number One issue patients on medication face
every day,” comments Mr. Friedman. “It enables them to monitor and thereby
protect themselves from overdoses, unexpected drug interactions, and sudden
emergencies. All the medication information they need is literally right at their
fingertips, and constantly refreshed for accuracy. And AI technology takes it a
step further by providing additional personalized data that can significantly add to
their health and well-being. "MyAIWatch is not simply a reporting device...it’s a proactive technology that communicates directly with the wearer’s medical team to confirm whether
prescribed dosages are being taken – and signals the wearer each time a dose is
required. It also alerts their doctor/s to any medical emergency that might arise.
As an added feature, first responders arriving on the scene of an accident or
an emergency can simply touch the MyAIWatch device and the patient's list of
medications will instantly become available – a critical factor when administering
proper life-saving medication for the injured. For patients in hospitals and skilled
care facilities, the device can be synced with the EHR (Electronic Health Records)
to ensure medication types and dosages are not mistaken.
A recent study published by the website My Medical Score reveals that
medication errors cost over $40 billion per year. And between 7,000 and 9,000
patients die from medication errors every year. "As a pharmacist, I've seen far too
many occasions where a physician prescribes a medication without understanding
the potential drug interactions that can put the patient in harm’s way,” adds Mr.
Friedman.
The company stated that MyAIWatch will be in full production and should be
available to the public and healthcare companies by the end of the first quarter of 2024.
Further updates will be announced as Beta Testing continues.
Additional information about MultiCorp is available on their website:
www.multicorpinternationalinc.com.
About MultiCorp International, Inc. MultiCorp International Inc operates its core business in the medical field but also will capitalize in sectors that demonstrate the potential to grow revenues and
profits for the company. The company looks to expand through acquisitions of
solid business models and management with the potential to grow exponentially.
The company will have additional subsidiaries that will eventually become their
own public entity, be sold, or continue to operate within MultiCorp. For further
information, contact:
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-
looking statements relate to, among other things, plans, and timing for the introduction or enhancement of our services and products, statements about
future market conditions, supply and demand conditions, and other expectations,
intentions, and plans contained in this press release that are not historical facts and
involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet
defined specifications. When used in this press release, the words "plan,"
"expect," "believe," and similar expressions generally identify forward-looking
statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in
technology and changes in pervasive markets.